Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer

摘要: Introduction: Although epidermal growth factor receptor (EGFR) inhibitors have progressively become a relevant therapeutic arm in the treatment of patients with advanced colorectal cancer, responses achieved are not durable and resistance invariably occurs. The advances sequencing technology allowed only more profound molecular tumor characterization but also identification different pathways involved drug disease progression. These biological improvements encouraged researchers to design clinical studies testing novel target therapies.Areas covered: After discussing results key Phase III randomized trials providing commentary on most promising agents (Sym004, MM-151, GA201 MEHD7945A), authors present future steps ahead toward real tailored treatment.Expert opinion: EGFR highly effective setting. negative predictive role RAS possibly BRAF mutations has...